Study Details

Back
Study ID OSI-774-107
Study Title A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva® (erlotinib) in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
Clinicaltrials.gov Identifier NCT00294736
Compound Name OSI-774 / erlotinib
Medical Indication or Disease Non-small cell lung cancer
Study Sponsor OSI Pharmaceuticals, LLC.
Collaborator Not Applicable
Study Start Date 31-Jan-2006
Study Completion Date 23-May-2014
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS